… with CVD risk reduction in the general population but have not been found to reduce CVD
risk in … Factors shown in the right panel may contribute to increased CVD risk in patients with …

… focus on the role of the EPA:AA ratio as a potential prognostic marker and treatment target in
cardiovascular disease. … EPA treatment in key cardiovascular conditions are summarized in …

… The REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl–… fatty acid (n3-FA)-based
therapy of eicosapentaenoic acid (EPA) demonstrated cardiovascular risk reduction …

… -PUFAs in diverse disease conditions ranging from cardiac disease, bronchial disorders, …
disease state-related factors could limit the response to EPA/DHA-supplementation by reducing …

… without a history of cardiovascular (CV) risk, elevated triglyceride … , stable ethyl ester of
eicosapentaenoic acid (EPA) that was … an expanded indication to reduce the risk of CV events in …

… Studies of patients with coronary artery disease receiving statin therapy suggest that EPA
may decrease plaque vulnerability and prevent plaque progression. EPA also decreased …

… acids as a potential method to reduce cardiovascular risk. These trials examined the effect of
eicosapentaenoic acid (EPA) and docosahexaenoic acid … and DHA reduced triglyceride (TG…

… cardiovascular health, notably in ischemic heart disease, and … cardiovascular disease
among the Eskimo population. Yet these people were healthy with little evidence of heart disease. …

… ethyl ester of eicosapentaenoic acid (EPA), reduced cardiovascular events in an at-risk
population by a … of the beneficial effects that EPA may offer beyond cardiovascular risk reduction. …

… Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among …
with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies. Eur …